Hardin Capital Partners LLC Purchases New Position in Danaher Corporation $DHR

Hardin Capital Partners LLC purchased a new stake in shares of Danaher Corporation (NYSE:DHR) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 2,825 shares of the conglomerate’s stock, valued at approximately $626,000.

Other hedge funds also recently modified their holdings of the company. BlackRock Inc. acquired a new stake in Danaher in the second quarter valued at $10,492,520,000. Jupiter Topco LLC acquired a new position in Danaher during the 2nd quarter worth about $1,456,317,000. Generation Investment Management LLP acquired a new position in Danaher during the 2nd quarter worth about $1,287,949,000. Bank of America Corp DE bought a new stake in shares of Danaher in the 2nd quarter valued at about $993,846,000. Finally, Legal & General Group Plc acquired a new stake in shares of Danaher in the second quarter valued at about $801,056,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR stock opened at $217.33 on Friday. The firm has a 50 day moving average of $210.88 and a 200-day moving average of $194.44. The company has a market cap of $152.78 billion, a price-to-earnings ratio of 38.60, a price-to-earnings-growth ratio of 2.72 and a beta of 0.76. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80.

Danaher (NYSE:DHR) last released its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.77 EPS. On average, equities analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio is 28.42%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on DHR shares. Stifel Nicolaus lowered their price objective on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Piper Sandler assumed coverage on shares of Danaher in a research report on Thursday, June 11th. They set a “neutral” rating and a $200.00 target price for the company. Guggenheim raised their price target on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. Finally, TD Cowen lowered their target price on shares of Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $235.23.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.